EvidenceAlerts

Kang EH, Choi HK, Shin A, et al. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford). 2019 May 16. pii: 5490653. doi: 10.1093/rheumatology/kez189. (Original study)
Abstract

OBJECTIVE: To compare cardiovascular (CV) risk among gout patients initiating allopurinol vs febuxostat.

METHODS: Using 2002-2015 Korean National Health Insurance Service data for the entire Korean population, we conducted a cohort study on gout patients initiating allopurinol or febuxostat. The primary outcome was a composite CV end point of myocardial infarction, stroke/transient ischaemic attack, or coronary revascularization. Secondary outcomes were individual components of the primary outcome, and all-cause mortality. We used propensity score-matching with a 4:1 ratio for allopurinol and febuxostat initiators to control for confounding. Competing risk analyses were done for non-fatal outcomes accounting for deaths.

RESULTS: We included 39 640 allopurinol initiators propensity score-matched on 9910 febuxostat initiators. The mean age was 59.1 years and 78.4% were male. The incidence rate per 100 person-years for the primary outcome was 1.89 for allopurinol and 1.84 for febuxostat initiators. The corresponding hazard ratio comparing allopurinol vs febuxostat initiators was 1.09 (95% CI: 0.90, 1.32). No significant difference was found for the secondary outcomes, including all-cause mortality (hazard ratio 0.96; 95% CI: 0.79, 1.16). Subgroup analyses limited to those at high CV risk and to equipotent-dose initiators (i.e. allopurinol ?300 mg/day vs febuxostat ?40 mg/day) showed similar results.

CONCLUSION: Overall, this large Korean population-based study suggests no difference in the risk of non-fatal CV events and all-cause mortality between allopurinol and febuxostat initiators. These findings are consistent with the recent US Medicare population study, although the current study population consisted of younger Asians.

Ratings
Discipline Area Score
Family Medicine (FM)/General Practice (GP) 6 / 7
General Internal Medicine-Primary Care(US) 6 / 7
Rheumatology 6 / 7
Internal Medicine 5 / 7
Comments from MORE raters

Internal Medicine rater

In spite of not being an experimental study, this article provides useful information regarding similar risk on cardiovascular events regardless of the hypouricemic drug selected. THe findings are supported by the proper design and sample size.
Comments from EvidenceAlerts subscribers

No subscriber has commented on this article yet.